We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+6.39%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$9.65B
AUM Growth
+$414M
(+4.5%)
Cap. Flow
+$77.2M
Cap. Flow
% of AUM
0.8%
Top 10 Holdings %
Top 10 Hldgs %
20.18%
Holding
1,150
New
121
Increased
363
Reduced
495
Closed
137
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lowe's Companies
LOW
|
+$53.4M |
| 2 |
Occidental Petroleum
OXY
|
+$38M |
| 3 |
Capital One
COF
|
+$36.7M |
| 4 |
Elevance Health
ELV
|
+$27.1M |
| 5 |
Kroger
KR
|
+$20.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Align Technology
ALGN
|
+$43.2M |
| 2 |
Microsoft
MSFT
|
+$36.6M |
| 3 |
Qualcomm
QCOM
|
+$34.8M |
| 4 |
Mastercard
MA
|
+$33.6M |
| 5 |
Merck
MRK
|
+$33.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.04% |
| 2 | Healthcare | 14.84% |
| 3 | Consumer Discretionary | 14.57% |
| 4 | Financials | 13.21% |
| 5 | Industrials | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNCE
526
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $1.94M | 0.02% |
197,434
-33,826
| -15% | -$333K |
|
527
Synopsys
SNPS
$71.6B
| $1.93M | 0.02% |
9,040
| – | – |
|
528
VICI Properties
VICI
$29.9B
| $1.92M | 0.02% |
+82,341
| New | +$1.85M |
|
529
Builders FirstSource
BLDR
$7.29B
| $1.91M | 0.02% |
58,658
-1,735
| -3% | -$47.1K |
|
530
ProPetro Holding
PUMP
$1.25B
| $1.89M | 0.02% |
464,873
+368,786
| +384% | +$2.01M |
|
531
Standard BioTools
LAB
$342M
| $1.88M | 0.02% |
253,538
-166,620
| -40% | -$1.15M |
|
532
LifeVantage
LFVN
$80.1M
| $1.88M | 0.02% |
155,752
-5,383
| -3% | -$72.8K |
|
533
Huntsman Corp
HUN
$2.1B
| $1.86M | 0.02% |
83,720
-151,678
| -64% | -$3.12M |
|
534
Mustang Bio
MBIO
$4.39M
| $1.84M | 0.02% |
780
+562
| +258% | +$1.39M |
|
535
Wells Fargo
WFC
$254B
| $1.84M | 0.02% |
+78,213
| New | +$1.93M |
|
536
TD Synnex
SNX
$19.9B
| $1.83M | 0.02% |
+26,176
| New | +$1.65M |
|
537
Ribbon Communications
RBBN
$386M
| $1.8M | 0.02% |
465,588
-75,775
| -14% | -$320K |
|
|
ECOM
538
DELISTED
CHANNELADVISOR CORPORATION
ECOM
| $1.79M | 0.02% |
123,747
-10,569
| -8% | -$175K |
|
|
CCRN
539
DELISTED
Cross Country Healthcare
CCRN
| $1.77M | 0.02% |
273,574
-54,741
| -17% | -$347K |
|
|
AERI
540
DELISTED
Aerie Pharmaceuticals
AERI
| $1.77M | 0.02% |
+150,790
| New | +$1.84M |
|
541
Akebia Therapeutics
AKBA
$338M
| $1.75M | 0.02% |
697,905
+230,762
| +49% | +$2.02M |
|
|
WWE
542
DELISTED
World Wrestling Entertainment
WWE
| $1.75M | 0.02% |
43,229
+280
| +0.7% | +$12.3K |
|
|
AKRO
543
DELISTED
Akero Therapeutics
AKRO
| $1.74M | 0.02% |
56,533
-7,943
| -12% | -$278K |
|
544
Darling Ingredients
DAR
$9.32B
| $1.74M | 0.02% |
48,316
-9,555
| -17% | -$292K |
|
545
Douglas Emmett
DEI
$2.05B
| $1.72M | 0.02% |
68,630
-35,407
| -34% | -$998K |
|
546
Ryman Hospitality Properties
RHP
$8.56B
| $1.72M | 0.02% |
46,641
-39,801
| -46% | -$1.41M |
|
547
Spyre Therapeutics
SYRE
$8.5B
| $1.71M | 0.02% |
+9,659
| New | +$1.79M |
|
|
AUD
548
DELISTED
Audacy, Inc.
AUD
| $1.7M | 0.02% |
1,056,032
+965,737
| +1,070% | +$1.45M |
|
549
LyondellBasell Industries
LYB
$19.5B
| $1.69M | 0.02% |
23,969
+2,712
| +13% | +$187K |
|
550
Independent Bank Corp
IBCP
$796M
| $1.69M | 0.02% |
134,187
-9,505
| -7% | -$133K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q3 2020 Portfolio in Review
As of Q3 2020, Jacobs Levy Equity Management held 1,150 positions worth $9.65B, up 4.5% from $9.23B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jacobs Levy Equity Management's Q3 2020 filing shows 121 new, 363 increased, 495 reduced and 137 closed positions. Its largest new stake was BioMarin Pharmaceuticals: 191,373 shares worth $14.6M. The largest sale was Align Technology, an estimated $43.2M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jacobs Levy Equity Management's largest Q3 2020 buy was BioMarin Pharmaceuticals: 191,373 shares worth $14.6M.
- Jacobs Levy Equity Management added most to Lowe's Companies in Q3 2020, an estimated $53.4M increase.
- Jacobs Levy Equity Management's biggest Q3 2020 reduction was Align Technology, cutting an estimated $43.2M.
- Jacobs Levy Equity Management fully exited Cloudera, Inc. in Q3 2020, selling an estimated $17.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 20% of its $9.65B portfolio in Q3 2020.
- Jacobs Levy Equity Management opened 121 new positions and closed 137 in Q3 2020.
- Jacobs Levy Equity Management's portfolio value rose 4.5% quarter-over-quarter to $9.65B.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2020, filed 16 Nov 2020.